Ureum shortage — LV supply status & alternatives

Ureum

—

In supply · Australia

Linola Urea

In supply · 🇦🇺 Australia · short in🌐 LV

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Marketing-authorisation holders
Active ingredient (INN)	Ureum
Brand names	Linola Urea
Therapeutic category	Auto-created by ZVA — Medicinal Product Availability Register (Latvia) scraper
Controlled substance	No

Registrations on file	6

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders6 registrations · 4 MA holders

Product	Strength	Form	Market	MA holder	Status
Eupatorium Purpureum Gran And Glob 5ch-30ch	—	tablet	🇨🇦 CA	DOLISOS LABORATOIRES S.A.	Active
Thaspium Aureum	—	tablet	🇨🇦 CA	HOMEOCAN INC.	Active
Eupatorium Purpureum-Injeel Liq	1.1ML	liquid	🇨🇦 CA	BIOLOGISCHE HEILMITTEL HEEL GMBH	Active
Eupatorium Purpureum-Injeel Forte Liq	1.1ML	liquid	🇨🇦 CA	BIOLOGISCHE HEILMITTEL HEEL GMBH	Active
Antimonium Sulfuratum Aureum	—	granules	🇨🇦 CA	DOLISOS CANADA INC.	Cancelled
Eupatorium Purpureum	—	granules	🇨🇦 CA	DOLISOS CANADA INC.	Cancelled

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.